Considering that around half of melanomas harbour mutations in BRAF V600E, the first targeted therapies approved by the U.S. Food and Drug Administration (FDA) were vemurafenib and dabrafenib, followed by BRAF/MEK inhibitor pairing treatment [22]. This evidence concerns the gene MAP2K7 and melanoma.